The maker of personal care products finalized its acquisition of Kenvue on Nov. 2.
It expects cost savings and revenue gains to total $2.1 billion over the next several years.
There's execution risk that the synergies Kimberly-Clark expects won't pan out.
Kimberly-Clark (NASDAQ:KMB) closed its acquisition of Kenvue, a consumer health company spun off from Johnson & Johnson (NYSE:JNJ), on Nov. 2.
The deal was valued at $48.7 billion, and Kimberly-Clark expects Kenvue to offer $2.1 billion in merger-related savings and revenue gains. That sounds good, but management still has to prove Kenvue is a value driver rather than just an expensive acquisition.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
Kimberly-Clark has brands found in homes across the world, including Kleenex, Huggies, and Cottonelle. Adding Kenvue's product portfolio to its lineup seems like a strong fit, as those are also items people generally don't think twice about reaching for when they need them. Kenvue's offerings include the brands Tylenol, Neutrogena, Listerine, and Band-Aid.
"This transaction brings together two iconic American companies to create a combined portfolio of complementary products, including 10 billion-dollar brands, that touch nearly half the global population through every stage of life," Kimberly-Clark said in a press release.
Interestingly enough, the main appeal of the deal may not be sales contributions. While Kimberly-Clark expects $2.1 billion in synergies (reinvesting $300 million), only $500 million of that is incremental profit expected to be obtained within the first four years after the acquisition closed.
The bulk of the acquisition's value lies in cost savings, which could be worth $1.9 billion and could be achieved within the first three years after the acquisition. Compared to those revenue assumptions, lower costs and higher margins will be easier to spot in quarterly reports.
Everything looks good on paper, but there's a difference between projections and execution. Kenvue was spun off from Johnson & Johnson in 2023, allowing the legacy brand to focus more on high-growth areas.
Kenvue may ultimately be a better fit for Kimberly-Clark's portfolio than for Johnson & Johnson's. But there's no guarantee that the synergies Kimberly-Clark expects will take shape.
Also, as Kimberly-Clark shared, the $2.1 billion figure mentioned earlier will take a few years to reach. But over the next several quarters, we'll start to get early previews of how successful the acquisition may be through margins, cost savings, debt levels, and cash flow.
It's too early to say whether Kimberly-Clark is a buy based solely on the Kenvue acquisition. But as it stands, it's a solid business that has seemingly grown even stronger thanks to the new brands it just acquired. Plus, while shareholders wait, Kimberly-Clark pays out a dividend currently yielding 4.7%.
Before you buy stock in Kimberly-Clark, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kimberly-Clark wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $315,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $896,981!*
Now, it’s worth noting Stock Advisor’s total average return is 768% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 20, 2026.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Kimberly-Clark. The Motley Fool has a disclosure policy.